BiomX Inc.
Company Information
Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 850 NEW BURTON ROAD, DOVER, DE, 19904
Mailing Address 850 NEW BURTON ROAD, DOVER, DE, 19904
Phone 972 545610935
Fiscal Year End 1231
EIN 823364020
Financial Overview
FY2024
-$17.73M
Net Income
$43.23M
Total Assets
$5.10
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | February 13, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 11, 2026 | View on SEC |
| 8-K Current report of material events | February 10, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | February 9, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 29, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | January 26, 2026 | View on SEC |
| 3 Initial insider ownership report | January 16, 2026 | View on SEC |
| 8-K Current report of material events | January 14, 2026 | View on SEC |
Material Events
8-K Strategy Change February 10, 2026
High Impact
- BiomX Inc. is streamlining its focus on lead clinical programs: BX004 (Phase 2b) and BX003 (preclinical/early clinical).
- Deconsolidation of the struggling Israeli subsidiary is projected to significantly reduce cash burn and extend the cash runway.
8-K Bankruptcy December 11, 2025
High Impact
- BiomX Inc.'s main Israeli subsidiary, BiomX Ltd., is initiating insolvency proceedings (a form of bankruptcy).
- This decision follows BiomX Inc.'s discontinuation of a major Phase 2b drug study due to financial constraints.
8-K Strategy Change December 8, 2025
High Impact
- BiomX Inc. discontinued the development of its main drug candidate, BX004, aimed at treating cystic fibrosis.
- The company is implementing significant cost-cutting measures, including a substantial reduction in its workforce.
Related Companies
Companies in the same industry (SIC: 2836)
AMGEN INC
AMGN Biological Products, (No Diagnostic Substances)
INTENSITY THERAPEUTICS, INC.
INTS Biological Products, (No Diagnostic Substances)
Vitro Biopharma, Inc.
Biological Products, (No Diagnostic Substances)
Surrozen, Inc./DE
SRZN Biological Products, (No Diagnostic Substances)
Twist Bioscience Corp
TWST Biological Products, (No Diagnostic Substances)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.